Cutaneous Adverse Effects of Neurologic Medications

Primary tabs

Cutaneous Adverse Effects of Neurologic Medications

Even after so many advancements in drug research and development, severe fatal drug reactions are still occurring on regular basis, affecting almost 8% of the general population and 2–3 % of hospitalized patients. This has generated a need for the physicians to identify, understand and treat patients with such drug outbreaks. Cutaneous side effects are most commonly observed with neurologic medications. In United States, approximately 7% of the patients are suffering from some or the other neurological problems and are taking neurologic medications.

Recently a review study has revealed the list of medications associated with cutaneous adverse effects and are approved by the US Food and Drug Administration (FDA) to treat the following neurologic disorders: Alzheimer disease, amyotrophic lateral sclerosis, epilepsy, Huntington disease, migraine, multiple sclerosis, Parkinson disease, and pseudobulbar affect.

Literature search was performed and specific FDA-approved drug or drug classes in combination with the terms ‘dermatologic,’ ‘cutaneous,’ ‘skin,’ or ‘rash” were used. PubMed and the Cochrane Database of Systematic Reviews were thoroughly assessed for the side effects ranging from those cited in randomized controlled trials to case reports. It befits neurologists, dermatologists, and other caregivers to be aware of the recorded cutaneous adverse reactions and their severity for proper management and potential need to withdraw the aggravating medication.

CNS Drugs March
Exploratory, Pramipexole, Rivastigmine Fingolimod Zonisamide, Neurologic disorders, Huntington disease, Neurologic Medications, Systematic Reviews, Randomized controlled, Cutaneous side effects
Log in or register to post comments